Legal & General Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-819
| Closed | -$4.29K | – | 3543 |
|
|
2024
Q1 | $4.29K | Hold |
819
| – | – | ﹤0.01% | 3309 |
|
|
2023
Q4 | $4.28K | Hold |
819
| – | – | ﹤0.01% | 3335 |
|
|
2023
Q3 | $12.9K | Sell |
819
-8,865
| -92% | -$159K | ﹤0.01% | 3209 |
|
|
2023
Q2 | $188K | Sell |
9,684
-16,732
| -63% | -$397K | ﹤0.01% | 2748 |
|
|
2023
Q1 | $749K | Sell |
26,416
-441
| -2% | -$13.1K | ﹤0.01% | 2218 |
|
|
2022
Q4 | $785K | Buy |
26,857
+400
| +2% | +$12.7K | ﹤0.01% | 2219 |
|
|
2022
Q3 | $699K | Sell |
26,457
-1,085
| -4% | -$39.8K | ﹤0.01% | 2255 |
|
|
2022
Q2 | $1.22M | Buy |
27,542
+81
| +0.3% | +$3.72K | ﹤0.01% | 2082 |
|
|
2022
Q1 | $1.36M | Sell |
27,461
-245
| -0.9% | -$11.8K | ﹤0.01% | 2132 |
|
|
2021
Q4 | $1.41M | Buy |
27,706
+547
| +2% | +$28.3K | ﹤0.01% | 2153 |
|
|
2021
Q3 | $1.51M | Buy |
27,159
+2,020
| +8% | +$99.4K | ﹤0.01% | 2143 |
|
|
2021
Q2 | $1.08M | Sell |
25,139
-7,683
| -23% | -$317K | ﹤0.01% | 2192 |
|
|
2021
Q1 | $1.37M | Sell |
32,822
-2,524
| -7% | -$117K | ﹤0.01% | 2116 |
|
|
2020
Q4 | $1.65M | Sell |
35,346
-969
| -3% | -$45.3K | ﹤0.01% | 1961 |
|
|
2020
Q3 | $1.54M | Buy |
36,315
+5,015
| +16% | +$219K | ﹤0.01% | 1879 |
|
|
2020
Q2 | $1.5M | Buy |
31,300
+2,466
| +9% | +$123K | ﹤0.01% | 1849 |
|
|
2020
Q1 | $1.33M | Buy |
28,834
+44
| +0.2% | +$2.21K | ﹤0.01% | 1754 |
|
|
2019
Q4 | $1.73M | Buy |
28,790
+1,755
| +6% | +$105K | ﹤0.01% | 1866 |
|
|
2019
Q3 | $1.53M | Buy |
27,035
+368
| +1% | +$20.7K | ﹤0.01% | 1829 |
|
|
2019
Q2 | $1.49M | Sell |
26,667
-284
| -1% | -$14.8K | ﹤0.01% | 1822 |
|
|
2019
Q1 | $1.36M | Sell |
26,951
-2,795
| -9% | -$124K | ﹤0.01% | 1858 |
|
|
2018
Q4 | $1.19M | Buy |
29,746
+416
| +1% | +$21.4K | ﹤0.01% | 1841 |
|
|
2018
Q3 | $2.03M | Buy |
29,330
+11,572
| +65% | +$877K | ﹤0.01% | 1693 |
|
|
2018
Q2 | $1.35M | Buy |
17,758
+1,385
| +8% | +$87.1K | ﹤0.01% | 1825 |
|
|
2018
Q1 | $859K | Buy |
16,373
+142
| +0.9% | +$8.26K | ﹤0.01% | 1945 |
|
|
2017
Q4 | $868K | Sell |
16,231
-172
| -1% | -$9.57K | ﹤0.01% | 1943 |
|
|
2017
Q3 | $978K | Buy |
16,403
+1,419
| +9% | +$85.8K | ﹤0.01% | 1874 |
|
|
2017
Q2 | $1.18M | Buy |
14,984
+563
| +4% | +$46K | ﹤0.01% | 1771 |
|
|
2017
Q1 | $1.2M | Buy |
14,421
+1,104
| +8% | +$82.1K | ﹤0.01% | 1727 |
|
|
2016
Q4 | $1.06M | Buy |
13,317
+6,368
| +92% | +$463K | ﹤0.01% | 1718 |
|
|
2016
Q3 | $486K | Buy |
6,949
+5,423
| +355% | +$300K | ﹤0.01% | 1708 |
|
|
2016
Q2 | $58K | Hold |
1,526
| – | – | ﹤0.01% | 2398 |
|
|
2016
Q1 | $60K | Hold |
1,526
| – | – | ﹤0.01% | 2330 |
|
|
2015
Q4 | $135K | Hold |
1,526
| – | – | ﹤0.01% | 1917 |
|
|
2015
Q3 | $112K | Hold |
1,526
| – | – | ﹤0.01% | 1976 |
|
|
2015
Q2 | $119K | Buy |
+1,526
| New | +$99.4K | ﹤0.01% | 1998 |
|
Other funds holding EGRX
NCM
ACM
Legal & General Group's EGRX Position: Q2 2024 in Review
Legal & General Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 819 shares — an estimated $4.29K sold.
Legal & General Group first reported a position in EGRX in Q2 2015 and held it in 36 quarters. The position peaked at $2.03M in Q3 2018. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.
- Legal & General Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Legal & General Group sold 819 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $4.29K.
- Legal & General Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 36 quarters.
- Legal & General Group's Eagle Pharmaceuticals, Inc. position peaked at $2.03M in Q3 2018.
- 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.
Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.